228 related articles for article (PubMed ID: 37540686)
1. Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study.
Ueapornpanith P; Buranakiti B; Chotayaporn T; Phrommintikul A; Yoodee V
PLoS One; 2023; 18(8):e0289721. PubMed ID: 37540686
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
[TBL] [Abstract][Full Text] [Related]
3. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of oral P2Y
Farmakis IT; Zafeiropoulos S; Doundoulakis I; Pagiantza A; Karagiannidis E; Moysidis DV; Stalikas N; Kassimis G; Michalis LK; Karvounis H; Giannakoulas G
Open Heart; 2022 Apr; 9(1):. PubMed ID: 35428703
[TBL] [Abstract][Full Text] [Related]
5. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
[TBL] [Abstract][Full Text] [Related]
6. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
[TBL] [Abstract][Full Text] [Related]
7. P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes.
Sachdeva A; Mutyala R; Mantri N; Zhu S; McNulty E; Solomon M
J Interv Cardiol; 2023; 2023():1147352. PubMed ID: 37251366
[TBL] [Abstract][Full Text] [Related]
8. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG
JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798
[TBL] [Abstract][Full Text] [Related]
10. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
Koshy AN; Giustino G; Sartori S; Hooda A; Feng Y; Snyder C; Dasgupta S; Kumar KR; Krishnamoorthy-Melarcode P; Sweeny J; Khera S; Serrao GW; Sharma R; Dangas G; Kini AS; Mehran R; Sharma SK
EuroIntervention; 2023 Mar; 18(15):1244-1253. PubMed ID: 36660810
[TBL] [Abstract][Full Text] [Related]
12. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
[TBL] [Abstract][Full Text] [Related]
13. Real-world evidence of switching P2Y12 receptor-inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry.
Kang J; Han JK; Yang HM; Park KW; Kang HJ; Koo BK; Choo EH; Lee JY; Park SD; Lim YH; Kim HM; Heo JH; Kim HS
BMC Cardiovasc Disord; 2023 Jan; 23(1):6. PubMed ID: 36624388
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome at High Bleeding or Ischemic Risk.
Akyuz S; Calik AN; Yaylak B; Onuk T; Eren S; Kolak Z; Mollaalioglu F; Durak F; Cetin M; Tanboga IH
Am J Cardiol; 2024 Jan; 210():241-248. PubMed ID: 37875237
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study.
Lam ASM; Yan BPY; Lee VWY
Clin Cardiol; 2021 Aug; 44(8):1072-1079. PubMed ID: 34041774
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
[TBL] [Abstract][Full Text] [Related]
17. P2Y12 Inhibitors for Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
Fujisaki T; Kuno T; Briasoulis A; Misumida N; Takagi H; Latib A
Tex Heart Inst J; 2023 May; 50(3):. PubMed ID: 37302149
[TBL] [Abstract][Full Text] [Related]
18. Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel.
Ng AK; Ng PY; Ip A; Lau KK; Siu CW
Stroke Vasc Neurol; 2022 Aug; 7(4):310-318. PubMed ID: 35264399
[TBL] [Abstract][Full Text] [Related]
19. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
[TBL] [Abstract][Full Text] [Related]
20. Translation of experimental cardioprotective capability of P2Y
Hjortbak MV; Olesen KKW; Seefeldt JM; Lassen TR; Jensen RV; Perkins A; Dodd M; Clayton T; Yellon D; Hausenloy DJ; Bøtker HE;
Basic Res Cardiol; 2021 May; 116(1):36. PubMed ID: 34037861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]